This company listing is no longer active
IO Biotech (IOBT) Stock Overview
A clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
IOBT Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
IO Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.17 |
| 52 Week High | US$2.79 |
| 52 Week Low | US$0.14 |
| Beta | 0.44 |
| 1 Month Change | -50.60% |
| 3 Month Change | -70.33% |
| 1 Year Change | -84.18% |
| 3 Year Change | -90.73% |
| 5 Year Change | n/a |
| Change since IPO | -98.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| IOBT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -17.5% | 4.1% | 1.6% |
| 1Y | -84.2% | 41.1% | 18.6% |
Return vs Industry: IOBT underperformed the US Biotechs industry which returned 21.5% over the past year.
Return vs Market: IOBT underperformed the US Market which returned 14.7% over the past year.
Price Volatility
| IOBT volatility | |
|---|---|
| IOBT Average Weekly Movement | 44.8% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: IOBT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IOBT's weekly volatility has increased from 31% to 45% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 78 | MBZ Zocca | www.iobiotech.com |
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company’s lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide to target T cells that recognize epitopes derived from Arginase 1, which is an immunoregulatory enzyme highly expressed in difficult-to-treat tumors associated with high levels of myeloid-derived suppressor cells, including renal cell carcinoma, head and neck, breast, pancreatic, ovarian, colorectal, and prostate cancers.
IO Biotech, Inc. Fundamentals Summary
| IOBT fundamental statistics | |
|---|---|
| Market cap | US$13.89m |
| Earnings (TTM) | -US$88.35m |
| Revenue (TTM) | n/a |
Is IOBT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IOBT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$88.35m |
| Earnings | -US$88.35m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.23 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 1,829.2% |
How did IOBT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/30 10:24 |
| End of Day Share Price | 2026/03/30 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IO Biotech, Inc. is covered by 2 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christopher Howerton | Jefferies LLC |
| Roger Song | Jefferies LLC |